TrialBritish journal of cancer2003

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.

X Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.